O'Neill Gilmore Neil 4
4 · Editas Medicine, Inc. · Filed Mar 6, 2023
Insider Transaction Report
Form 4
O'Neill Gilmore Neil
DirectorCEO
Transactions
- Award
Common Stock
2023-03-02+50,000→ 136,655 total - Award
Stock Option (right to buy)
2023-03-02+150,000→ 150,000 totalExercise: $8.72Exp: 2033-03-01→ Common Stock (150,000 underlying)
Footnotes (2)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
- [F2]This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.